Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
about
Methotrexate for ankylosing spondylitisComparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis: A Systematic Review and a Network Meta-AnalysisComparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysisAnkylosing spondylitis in iran; late diagnosis and its causes.Indirect comparisons: a review of reporting and methodological qualityMyelitis and optic neuritis induced by a long course of etanercept in a patient with rheumatoid arthritis.Extraction of electronic health record data in a hospital setting: comparison of automatic and semi-automatic methods using anti-TNF therapy as model.Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis.The economic burden of TNFα inhibitors and other biologic treatments in Norway.2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: Protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment.Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.Increased occurrence of spinal fractures related to ankylosing spondylitis: a prospective 22-year cohort study in 17,764 patients from a national registry in SwedenEconomic considerations of the treatment of ankylosing spondylitis.Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis.Passive immunization with a nicotine-specific monoclonal antibody decreases brain nicotine levels but does not precipitate withdrawal in nicotine-dependent rats.Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitisLong-term use of adalimumab in the treatment of rheumatic diseases.Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis.Simultaneous multioutcome synthesis and mapping of treatment effects to a common scale.Pathogenesis of ankylosing spondylitis.Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population.Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis.Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.The economic burden of the ankylosing spondylitis in the Czech Republic: comparison between 2005 and 2008.Henoch-Schönlein purpura complicating adalimumab therapy for Crohn's disease.Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.The safety of anti-TNF agents in the elderly.Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective.Are there new emerging drugs for ankylosing spondylitis or spondyloarthritis?Evaluation of potential retinal toxicity of adalimumab (Humira).Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-α therapy.Abnormal high-expression of CD154 on T lymphocytes of ankylosing spondylitis patients is down-regulated by etanercept treatment.Association of polymorphisms in TNF and GRN genes with ankylosing spondylitis in a Chinese Han population.Effect of tumor necrosis factor-α inhibitors on ambulatory 24-h blood pressure.Acceptability of switching adalimumab from a prefilled syringe to an autoinjection pen.Genetics in TNF-TNFR pathway: A complex network causing spondyloarthritis and conditioning response to anti-TNFα therapy.
P2860
Q24200564-797F1D71-FAC4-42C5-A2ED-AEE45CD1D270Q26764820-CC126D86-2A8E-42AB-8590-F25F1AF4E014Q26828622-5EE8B850-0E30-40BF-A090-685F10865081Q33640595-7CB4B3B1-68B2-4091-8E58-FEA88876853EQ33750311-F69492EC-E46D-4553-9BFD-54335708AA3FQ34023923-047A745A-CF98-4E9A-B195-E334B797E217Q34572340-25A13F32-D48B-4D5E-A153-F1CBC582108FQ34728162-DA221A8B-7B30-4464-848F-EF39A11B3883Q35205411-0D318E10-67AD-416E-8180-D0776DBC83BEQ35567870-60DC74B3-F8B6-4DAE-8B40-284D2E7A3BECQ35838797-CE32E095-E136-4FFD-9AC0-AD078AB27520Q36477447-4289580F-8031-4EE6-8031-0AF8AA97B4EEQ36608425-6AC7B677-A9D9-4018-8106-B7B0F8DAFA96Q36731613-058AE02B-5C38-4971-A81F-5CDBBB1940BCQ37215981-43CADC61-C65A-4FA3-9E9C-BCB22311D6DFQ37260093-9F968403-1E57-46C0-97BA-40C96717BD3CQ37294508-577C1927-D307-4BDD-808D-FCD61EFBD686Q37358124-29C554A0-F3C5-41B0-A8EC-074FB373B868Q37453012-9893E721-EC05-49DB-87F9-0EF28A951807Q37709832-019B64DE-E121-4D03-9355-A247EA696104Q37762157-DC1707B2-1DA4-44B5-9FC0-0E917EE5ABA8Q38034134-F085A067-5F67-424A-8F16-11526EE8DC2CQ38081733-C7EE3C9D-1C80-4254-AB05-C0D7563AC095Q38098483-44E4B142-22B7-4856-A116-80E975D7BB4EQ38424589-64B07612-E262-4D06-811A-EFE54847043AQ38927751-B785D4AC-2AF1-4883-9016-321B9EB9521CQ38993250-5ECF499A-B290-41D8-9363-E9BF6FED21E9Q39486298-017611EB-EFB4-4D1D-8468-0DF7BEF97E5EQ42730509-87B258B3-15E8-4A92-A1FE-120B54880E06Q43133532-F7735733-F502-4A55-9A66-D167D0638DDCQ43688354-70C88250-5EF0-44CB-88A4-6CE0212C7A0AQ45893661-5C020AD5-7134-41D7-897A-BEFA1E247E14Q45977892-B75C4D07-5719-40E8-8355-608989CA6FEAQ46083924-FB1DBD9C-C20B-481B-A4C8-73A125F995B5Q46941367-CD9FFC8A-646D-49AD-82D2-E91B194CCAAFQ47733309-F8B7B1E7-DC28-4D7F-ADE0-E5D528351E39Q48137341-85250BCB-087A-4465-9217-A44AEFC778E7Q51329120-3308473C-DF36-483B-947D-AF2DE469F36BQ51918489-42BD35E1-8CE8-40A3-AAAB-9A86101EDC6BQ52341767-0B1869D1-8E3E-495F-A9F5-0CA4ECAB5239
P2860
Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Adalimumab, etanercept and inf ...... eview and economic evaluation.
@en
type
label
Adalimumab, etanercept and inf ...... eview and economic evaluation.
@en
prefLabel
Adalimumab, etanercept and inf ...... eview and economic evaluation.
@en
P2093
P356
P1476
Adalimumab, etanercept and inf ...... eview and economic evaluation.
@en
P2093
P Dagenais
R Mujica Mota
P304
1-158, iii-iv
P356
10.3310/HTA11280
P577
2007-08-01T00:00:00Z